Major shareholders: BIGN HLDG

NameEquities%Valuation
Regal Funds Management Pty Ltd.
13.87 %
113,999,655 13.87 % 10 M $
Australian Ethical Investments Ltd. (Investment Management)
10.03 %
82,398,877 10.03 % 8 M $
SQN Investors LP
9.120 %
74,940,121 9.120 % 7 M $
MA Investment Management Pty Ltd.
3.613 %
29,683,410 3.613 % 3 M $
15,311,197 1.863 % 1 M $
Estate of Cohen Geoffrey
0.9245 %
7,596,480 0.9245 % 695 838 $
Aotearoa Investment Co. Pty Ltd.
0.6330 %
5,201,553 0.6330 % 476 462 $
SBCVC Fund IV Pte Ltd.
0.4538 %
3,729,152 0.4538 % 341 590 $
Southern Cross Iif Trusco Pty Ltd.
0.4208 %
3,457,332 0.4208 % 316 692 $
Isle of Wight Pty Ltd.
0.3087 %
2,536,748 0.3087 % 232 366 $
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional36.64%
Other2.74%
Individuals2.25%
Unknown58.37%

Based on 1000 largest holdings

Geographical origin of shareholders

Australia 28.25%
United States 9.12%
Individuals 2.88%
United Kingdom 0.92%
Singapore 0.45%

Based on 1000 largest holdings

Logo BIGN HLDG
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
Employees
495
Sector
-
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW